Skip to main content

Table 1 Demographics and clinical baseline characteristics

From: Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial

  Atorvastatin (n = 36) Placebo (n = 32)
Age, years 40.4 (34.8,45.5) 43.0 (38.1,52.0)
Male sex, n (%) 15 (41.7%) 15 (46.9%)
Smoking history (pack years) 24 (14,34) 21 (10,30)
Duration of asthma symptoms, years 24.0 (14.5,32.5) 19.5 (12.5, 38.5)
Atopic, n (%) 18 (54.5%) 21 (67.7%)
Total IgE (IU/ml) 82 (19,192) 197 (76,517)
Use of inhaled corticosteroid at screening, n (%) 19 (52.8%) 16 (50.0%)
Equivalent beclometasone dose at screening, μg 100 (0,400) 200 (0,800)
Use of LABA at screening, n (%) 8 (22.2%) 14 (43.8%)
Pre-bronchodilator FEV1 % predicted 84 (71,98) 79 (65,92)
FEV1 % reversibility 11 (6,16) 12 (8,19)
Serum cotinine (ng/mL) 85 (78,90) 82 (79,94)
  1. Definition of abbreviations: FEV1, Forced Expiratory Volume in one second; LABA, long-acting beta2-agonist
  2. Data represented as median (IQR) unless specified.
  3. Number of randomized subjects with at least one post-baseline assessment of PEF